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Background: People intending to travel may seek information on malaria prevention from a range of sources. To
ensure the best protection, this information needs to be reliable, up-to-date, consistent, and useful to their decision
making. This study appraises current international and national guidelines written in English for malaria prevention
in travellers, and whether any recommendations conflict.
Methods: We systematically identified national or international English-language guidelines on malaria prevention
in travellers to July 2013 using standard and multiple searching methods. We critically appraised guidelines using
the AGREE II tool, and report inconsistent recommendations within guidelines.
Results: We identified five sets of English-language guidelines on preventing malaria for travellers. Assessment
against AGREE II indicate that all of the guidelines fall short of internationally accepted standards in guideline
development: none include a transparent description of methods; only one describes sources of funding or
potential conflicts of interest; and only one includes formal presentation of the evidence alongside transparent
assessment of the quality of that evidence. There were a number of important discrepancies between guidelines,
and some omit information about effectiveness, safety and adverse effects of chemoprophylaxis options.
Conclusions: The methods used for developing guidelines for malaria prevention in travellers lags behind current
internationally recognized standards. Healthcare professionals as well as travellers themselves could be better
informed if guidelines were more systematic and transparent summaries of the current knowledge on drug
interventions in relation to effects, safety, administration and contra-indications.
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In the UK, approximately 2,000 episodes of malaria are
recorded each year in people returning from travel to
endemic countries, and travellers still die from malaria
[1]. Travellers can reduce their risk of malaria illness by
taking antimalarial drugs throughout their time abroad
as prophylaxis, and by various non-drug interventions
which reduce mosquito bites.
People intending to travel may access information on
malaria prevention through on-line resources, by visiting
their own doctor, through specialist travel clinics, or* Correspondence: meravkliner@nhs.net
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unless otherwise stated.through various travel operators [2]. To ensure the best
protection, this information needs to be reliable, up-to-
date and based on the best available research evidence.
In the UK, health workers will usually follow guidelines
developed by Public Health England, or available through
on-line travel sites such as the National Travel Health
Network and Centre (NaTHNaC). However, many other
guidelines are available developed by other national or
international bodies.
Travellers to malaria endemic settings require informa-
tion that enables them, and convinces them, to choose
the interventions that are most effective and safe for
them. This is likely to involve some quantification of the
relative benefits and harms of each intervention. Totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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information in a clear and user-friendly format [3].
In this study, we aim to a) appraise the available national
and international English-language guidelines on malaria
prevention against international best practice in guideline
development, b) evaluate the degree of consistency or
conflict between guidelines, and c) consider how well the
information facilitates informed decision making.
Methods
Identification of guidelines
Two authors (MK, KP) searched independently for inter-
national or national guidelines for malaria prevention in
travellers using: Google, the websites of major public
health bodies from English-speaking non-endemic coun-
tries (the UK, USA, Australia, New Zealand, Scotland
and Canada), the TRIP database, the National Guideline
Clearing House, and pubmed (using the search terms:
malaria AND (prevent* OR prophylax*) AND guid* AND
travel) for articles published until the end of July 2013.
Guidelines limited to malaria prevention in sub-groups
(such as children), or in languages other than English,
were excluded.
Agree II appraisal of guidelines
Two authors (MK, KP) independently appraised each
identified guideline using the AGREE II guideline ap-
praisal tool [4]. The AGREEII tool appraises guidelines
against 23 criteria across six domains; scope and purpose,
stakeholder involvement, rigour of development, clarity
of presentation, applicability, and editorial independence.
Each reviewer first assigned a score between one and
seven for each criteria (one being the lowest and seven
the highest), and the scores of both reviewers were then
combined and converted into a percentage score for each
domain.
Agreement between guidelines
Two authors (MK, KP) independently reviewed each
guideline to identify both explicit and implicit recom-
mendations relating to prevention of malaria. Explicit
recommendations were classified as those where some-
thing was clearly being advised (for example, “Spraying
before bedtime, combined with the use of a vaporiser
is recommended”). Implicit recommendations were
classified as statements where judgements are being
made (for example, “Insect repellent applied to cloth-
ing is effective for longer than it may be on the skin”).
Two reviewers mapped recommendations to a standar-
dised table independently and compared and contrasted
them. Discrepancies were addressed through discussion
between the two reviewers and where discrepancies
could not be resolved, a third reviewer (DS) was
consulted. Two reviewers (MK, KP) compared therecommendations made by each of the guidelines to
identify any conflicts between sets of guidelines.
Results
Five guidelines met our inclusion criteria, developed by:
the World Health Organization (WHO) [5], the Public
Health Agency of Canada (CA) [6], the Hong Kong
Centre for Health Protection (HK) [7], the Public Health
England advisory committee on malaria prevention (UK)
[8] and the Centre for Disease Control (USA) [9].
We excluded an article providing advice for travellers
from New Zealand, as it was not official national guid-
ance [10], and although our PUBMED search suggested
there may be guidelines from Japan, The Netherlands
and Spain, these were unavailable in English. No guid-
ance was identified from Australia or Scotland. A brief
summary of these guidelines is outlined in Table 1.
Agree II appraisal of guidelines
The summary AGREE II scores for each of the five guide-
lines are shown in Table 2.
Domain 1: Scope and purpose
All five guidelines covered both drug and non-drug inter-
ventions to prevent malaria in travellers, and all aimed to
assist clinicians as they advise travellers. The UK and HK
guidelines provided the most complete description,
clearly outlining the objectives, health issue and target
population to which the guidelines apply.
Domain 2: Stakeholder involvement
All guidelines gave a named list of the individuals who
primarily authored the document, although only the UK
guidelines stated the roles and responsibilities of these
individuals. Three guidelines (HK, USA and WHO) also
referred to working groups or external contributors but
these were not named. None of the guidelines reported
involvement of the target population (travellers).
Domain 3: Rigour of development
None of the guidelines included a Methods section.
None described methods to systematically search for
and appraise evidence, or to move from evidence to
formulating recommendations. None of the documents
described external peer review prior to publication, and
only the WHO guideline made reference to a process for
future updates.
The Canadian guideline presented the evidence base
summarized in GRADE tables. All other guidelines sum-
marized evidence in text form, with variable levels of
referencing provided to validate recommendations. USA
and WHO guidelines provide no references, HK provide
some references and UK guidelines provide a reference
for many of the recommendations made.
Table 1 Brief summary of guidelines
Canada Hong Kong UK USA WHO






Stand-alone guidance Within ‘Yellow Book’ on
travel health, chapter on




and health’; chapter on ‘malaria’
and subsection on




















6 named chapter authors,
with wide range of editorial
staff, CDC and external
contributors
2 editors, 3 assistants and a
wide range of WHO and
external personnel







prevention of malaria in
travellers
Drug and non-drug preven-
tion of malaria in travellers
Drug and non-drug
prevention of malaria in
travellers
Length 90 pages Split into two
papers, total 58
pages
97 pages Split into 2 chapters, total 22
pages
Split into 2 chapters, total 26
pages
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fects of interventions to some extent, although the level
of detail, particularly around safety was highly variable.
The Canadian and WHO guidelines gave some risk esti-
mates for the potential benefits and harms.
Domain 4: Clarity of presentation
All of the guidelines presented some clear recommenda-
tions that were unambiguous and specific, and clearly iden-
tifiable. However, all guidelines also included discussions of
options without clear recommendations, or implied rec-
ommendations incorporated into the text and without
clear signposting. The Canadian guidelines were presented
most clearly, listing all explicit recommendations in a table.
Domain 5: Applicability
None of the guidelines discussed the resource implica-
tions of the recommendations, and none describedTable 2 AGREE II scores for guidelines
AGREE II domain Canada H
Domain 1: Scope and purpose1 14% 7
Domain 2: Stakeholder involvement2 17% 3
Domain 3: Rigour of development3 20% 9
Domain 4: Clarity of presentation4 72% 6
Domain 5: Applicability5 4% 4
Domain 6: Editorial independence6 0% 0
1Scope and purpose concerns the overall aim of the guideline, the scope of the qu
2Stakeholder involvement looks at the extent to which the guideline development
intended users of the guideline and those affected by the recommendations.
3Rigour of development examines the process used to search for, synthesize, and a
4Clarity of presentation concerns the general language, structure, and format of the
5Applicability requires adequate consideration of the likely barriers and facilitators t
improve uptake and implementation.
6Editorial independence concerns the adequate declaration and management of po
group members.potential barriers or facilitators to implementation. None
presented audit criteria. Only the USA guideline pre-
sented an outline of the advantages and disadvantages of
each drug in a user-friendly table.Domain 6: Editorial independence
Only the USA guideline described the sources of funding,
and made any reference to potential conflicts of interest
among guideline developers. The remaining guidelines
said nothing, and therefore scored zero for this domain.Agreement or disagreement between guidelines
a. Drug interventions for malaria prevention
A summary of the drug recommendations made by each
of the guidelines has been presented in Additional file 1.
The main areas of conflict and omission are related to in-
formation on effectiveness, safety and contraindications:ong Kong UK USA WHO
2% 92% 44% 50%
3% 58% 39% 53%
% 14% 22% 12%
1% 53% 47% 50%
% 13% 13% 4%
% 0% 50% 0%
estions, and the target audience.
process included the views of all appropriate stakeholders, including the
ppraise evidence, formulate recommendations, and keep them updated.
guideline.
o implementation, including resource considerations, and advice or tools to
tential conflicts of interest related to the funding body or the guideline
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doxycycline and mefloquine are effective against
chloroquine resistant falciparum malaria. Two
guidelines quantify this: the Canadian guidelines
state that they are 95% effective and the UK
guidelines state that they are 90% effective, each
referencing different documents.
– The Canadian, Hong Kong and USA guidelines state
that atovaquone-proguanil has an excellent safety
profile, with only the Canadian guidelines quantifying
that 8% to 15% of individuals experience nausea,
vomiting, abdominal pain or diarrhoea. The
guidelines state that the most common side effects
are headache and gastrointestinal upsets, but again
do not quantify this.
– Although the Canadian guideline outlines that
atovaquone-proguanil has an excellent safety profile,
it outlines that it should be used in caution in
patients with HIV and liver disease. This is not
discussed in other guidelines;
– The US guideline states that atovaquone-proguanil
cannot be used in children under 5 kg, whereas all
other guidelines state 11 kg as the cut-off;
– All guidelines state that doxycycline may be
photosensitising and can lead to a rash, however no
guidelines quantify this risk;
– All guidelines state that doxycycline may lead to
gastrointestinal upset and oesophageal ulceration,
however no guidelines quantify this risk;
– The UK guideline states that doxycycline is
contraindicated in children under 12 years, while all
other guidelines say 8 years;
– All guidelines state that mefloquine can lead to
major neuropsychiatric side effects such as seizure,
psychosis and suicidal ideation. The Canadian and
WHO guidelines quantify this. Canadian guidelines
suggest that 1 in 6,000 to 13,000 have seizure or
psychosis; and WHO guidelines suggest severe
neuropsychiatric disturbance in 1 in 10,000.
– The Canadian, Hong Kong and USA guidelines state
that mefloquine can lead to minor side effects such
as nausea, strange vivid dreams, dizziness, mood
changes, insomnia, headache and diarrhoea. The UK
and WHO guidelines do not mention this. Only the
Canadian guideline quantifies this, suggesting that
95% of people have no or mild, temporary side
effects, with 1 in 250 to 500 having mild
neuropsychological reactions e.g. anxiety or mood
change;
– The US guideline states that mefloquine can be
given to all ages, while other guidelines state it
cannot be used in children below 5 kg;
– Stand-by treatments is recommended as being
valuable in all guidelines, although the USAguidelines provide very little information regarding
this.
b. Non–drug interventions for malaria prevention
A full outline of the non-drug recommendations made by
each of the guidelines has been presented in Additional
file 2. There is varying levels of consensus between the
guidelines, with a number of significant conflicts.
The main conflicts and omissions are that:
– The WHO guidelines states insecticide-treated
clothing lasts longer than skin applied insecticide,
whereas UK guidelines states the opposite. Other
guidelines provide no recommendations regarding this;
– Concentrations of DEET recommended in children
vary from 10% (CA, HK) to 50% (UK), and in adults
vary from 35% (CA, HK) to 50% (UK, USA) in
adults. WHO guidelines state that DEET should be
used according to manufacturers’ recommendations;
– The Canadian and WHO guidelines state that DEET
can be used at any age, while the UK and USA
guidelines state it should be restricted to children
over the age of 2 months. Hong Kong guidelines do
not provide recommendations on age limits of
DEET;
– The WHO guidelines state that no other protection
is required if a hotel is air-conditioned. The UK and
USA guidelines imply that malaria transmission is
reduced in air-conditioned rooms, and the Canadian
and Hong Kong guideline do not provide recom-
mendations on air-conditioning;
– Light covering clothing is recommended by Canada
and Hong Kong, while the UK guidelines state this
is not effective. USA and WHO guidelines do not
provide recommendations on the use of light
covered clothing.
Discussion
Appraisal of the five guidelines using the AGREE II tool
indicates that all of the English guidelines surveyed (from
national bodies and international bodies) fall short of
internationally accepted standards in guideline develop-
ment. None include a transparent description of methods
used, only one describes sources of funding and potential
conflicts of interest, and only one includes formal presen-
tation of the evidence alongside transparent assessments
of the quality of that evidence. There were a number of
important discrepancies between guidelines; and some
omit information about effectiveness, safety and adverse
effects of chemoprophylaxis options.
Moving from research evidence to healthcare recom-
mendations is not straightforward. High quality evidence
that an intervention is effective does not automatically
lead to a strong recommendation to implement it, and
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mendation [11]. The process instead involves a series of
judgements by the guideline panel, and may take into ac-
count the importance of the condition, the applicability
of the evidence to the population group, and cost. These
judgements are influenced by the values and preferences
of the guideline developers, and consequently it is not
unexpected that different guidelines developed by differ-
ent teams will have discrepancies and inconsistencies as
highlighted in this paper. More problematic however, is
the fact that in most of these guidelines it is unclear what
evidence was reviewed, what the strengths and weak-
nesses of that evidence was, or the basis of the judge-
ments may be the panels.
A second clear deficiency common across guidelines
was the lack of user-friendly resources for implementa-
tion. Although most guidelines stated that they should be
used by healthcare workers and travellers to identify the
most suitable interventions for individuals, most did not
provide adequate information to help these decisions be-
tween different strategies, and quantified estimates of the
proportion of people who would be likely to benefit or be
harmed by an intervention were rarely given. This was
particularly true of drug interventions where side effects
are often one of the most important factor influencing
choice [12,13]. Therefore, they did not give adequate in-
formation about when chemoprophylaxis should be used,
and if so, which drug should be given. Shared decision
making between healthcare workers and patients may be
beneficial where evidence is scarce or conflicting and can
be encouraged by adapting guidelines to including infor-
mation for healthcare workers on how to discuss options
with patients, and ensuring that the guidelines are access-
ible to patients such as through patient support tools
[14,15].
In addition there were a number of inconsistencies or
discrepancies between guidelines. Most were omissions
of information, but some reflected different or conflicting
recommendations. Identifying these may suggest this is
where the evidence is weak or limited, and expert judg-
ment alone has been the main driver of the recommenda-
tion. Being clear and transparent about the presence or
absence of high quality evidence behind a recommenda-
tion helps identify priority research questions, and stimu-
late a genuinely useful research agenda.
One limitation of this study is that we only included
English-language guidelines. Italian guidelines, published
as a summary in English after the literature search was
conducted for this paper, outlines that national and inter-
nationals guidelines have moved in a varying degree away
from routinely recommending chemoprophylaxis to a
greater use of a wide range of preventative methods [16].
There may be a difference in recommendations between
English-language and non-English-language guidelinesand using these methods in a cross-language comparison
may provide help in assuring guideline quality and stan-
dardising recommendations for preventing malaria.
Conclusions
We evaluated five sets of guidelines written in English on
the prevention of malaria for travellers. Guidelines had a
number of omissions and conflicts, and were not clearly
based on evidence. Healthcare professionals and travellers
would benefit from consistent, easy to use guidelines,
based clearly on evidence, and outlining current know-
ledge on effectiveness of interventions, safety, administra-
tion and contra-indications.
Additional files
Additional file 1: Consensus between guidelines for drug
interventions.
Additional file 2: Consensus between guidelines for non-drug
interventions.
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